Factory Supply Tirzepatide Peptide Bulk Powder CAS2023788-19-2 Diabetes Treatment Raw Material

Tirzepatide (CAS 2023788-19-2) is a novel, dual-acting glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This synthetic peptide is clinically proven for the treatment of type 2 diabetes mellitus (T2DM) and chronic weight management. As a high-purity pharmaceutical intermediate, our Tirzepatide offers exceptional efficacy in glycemic control and weight reduction, positioning it as a breakthrough therapeutic agent in metabolic disorder management.

Tirzepatide (CAS 2023788-19-2) is a novel, dual-acting glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This synthetic peptide is clinically proven for the treatment of type 2 diabetes mellitus (T2DM) and chronic weight management. As a high-purity pharmaceutical intermediate, our Tirzepatide offers exceptional efficacy in glycemic control and weight reduction, positioning it as a breakthrough therapeutic agent in metabolic disorder management.

Changsha XiJun Co., Ltd.

High-Tech Peptide Innovator

Based in Changsha, Hunan, we are a dynamic biotech enterprise focused on R&D and production of premium peptide products for pharmaceutical, nutraceutical, and cosmetic applications.

Core Strengths:

• Advanced peptide technology
• Rigorous quality control (cGMP standards)
• Expert R&D team
• End-to-end solutions from raw materials to finished products

Mission:
"Technology Powers Health, Quality Defines the Future"  — advancing global wellness through cutting-edge peptide science.

Brief Introduction of Tirzepatide:

Tirzepatide is a novel dual agonist of the GLP-1 and GIP receptors, primarily used to treat type 2 diabetes, offering both glucose control and weight loss benefits. It activates intestinal hormone receptors to regulate insulin secretion, delay gastric emptying, and suppress appetite, achieving both blood sugar control and weight management.

Mechanism of Action and Characteristics:

1. Dual Receptor Activation:
Tirzepatide acts simultaneously on both the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. GLP-1 receptor activation promotes insulin secretion and inhibits glucagon release, while GIP receptor activation enhances glucose uptake by adipose tissue, resulting in synergistic glucose lowering.

2. Long-Lasting Effect:
Structural modifications have resulted in a longer half-life, enabling once-weekly subcutaneous administration and improving adherence.

3. Significant Weight Loss:
Clinical trials have shown that Tirzepatide can simultaneously lower blood sugar and help patients lose an average of 10%-15% weight (dose-related), outperforming some single-target drugs.

Tirzepatide (LY3298176) is a dual glucose-dependent  polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes. Tirzepatide (LY3298176) shows significantly better efficacy with regard to glucose control and weight loss than do Dulaglutide. Tirzepatide, also known as LY 3298176, is a dual glucose-dependent  polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide has a greater affinity to GIP receptors than to GLP-1 receptors, and this dual agonist behavior has been shown to produce greater reductions of hyperglycemia compared to a selective GLP-1 receptor agonist. Signaling studies reported that tirzepatide mimics the actions of natural GIP at the GIP receptor. Tirzepatide was approved for improving blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise.  Product Tirzepatide (LY3298176) is a dual glucose-dependent  polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes. Tirzepatide (LY3298176) shows significantly better efficacy with regard to glucose control and weight loss than do Dulaglutide. Tirzepatide, also known as LY 3298176, is a dual glucose-dependent  polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide has a greater affinity to GIP receptors than to GLP-1 receptors, and this dual agonist behavior has been shown to produce greater reductions of hyperglycemia compared to a selective GLP-1 receptor agonist. Signaling studies reported that tirzepatide mimics the actions of natural GIP at the GIP receptor. Tirzepatide was approved for improving blood sugar control in adults with type 2 diabetes, as an additio

1.How to confirm the product quality before placing an order?
A: We can provide you with the sample. Also, we have the inspection report issued by the authoritative third-party testing agency.

2: What's your MOQ?
A: It depends on different products. We accept sample orders. Also for some products, we can provide you with a sample.

3:Do you provide after-sales service?
A: We provide 24-hour customer service. If you encounter any product quality problems or transportation problems, please feel free to contact us.

4:How about delivery time and method?
A: We usually ship within 3-5 working days after payments. We can make ships by sea, air, and express. Also can make door-to-door shipping.

5:How to solve the after-sale disputes?

n to diet and exercise.

Retatrutide is a new type of multi-target peptide drug developed by Eli Lilly and Company of the United States, it is a triple receptor agonist of GLP-1R/GIPR/GCGR. Its core mechanism is to regulate the metabolic process by activating glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon (GCG) receptors at the same time, and is used for the treatment of obesity and type 2 diabetes. The following are its key features: